Menin-MLL inhibitor 19

Cat. No.:	HY-139076
CAS No.:	2360487-93-8
Molecular Formula:	$C_{30}H_{34}F_3N_7O_4S$
Molecular Weight:	645.7
Target:	Epigenetic Reader Domain
Pathway:	Epigenetics
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 200 mg/mL (309.74 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	1.5487 mL	7.7435 mL	15.4871 mL
	5 mM	0.3097 mL	1.5487 mL	3.0974 mL
	10 mM	0.1549 mL	0.7744 mL	1.5487 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 5 mg/mL (7.74 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 5 mg/mL (7.74 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 5 mg/mL (7.74 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Menin-MLL inhibitor 19, a potent exo-aza spiro inhibitor of menin-mll interaction, example A17, extracted from patent WO2019120209A1. Menin-MLL inhibitor 19 can be used for the reseaech of various diseases, such as cancer, myelodysplastic syndrome (MDS) and diabetes[1].

IC_{50} & Target

IC_{50}: menin-mll interaction[1]

REFERENCES

[1]. Xuedong Dai, et al. Exo-aza spiro inhibitors of menin-mll interaction. Patent WO2019120209A1

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA